Research Spending Post-MiFID II: Is COVID-19 the Straw that Broke the Camel’s Back?
[ad_1] The toxic cocktail of unanticipated consequences stemming from MiFID II research rules has a potent new ingredient: the coronavirus market drawdown. This may accelerate a regulatory review of MiFID II…